ViroVet Overview

  • Founded
  • 2015
Founded
  • Status
  • Private
  • Employees
  • 18
Employees
  • Latest Deal Type
  • Series B
  • Latest Deal Amount
  • $6.67M
Latest Deal Amount
  • Investors
  • 10

ViroVet General Information

Description

Developer of antiviral drugs designed to control the spread of viral diseases in livestock. The company's drugs are meant for diagnosing respiratory disease complexes and also serves as an innovative vaccine for viral infections in swine, enabling livestock producers, governmental and international organizations to acquire a multi-faceted arsenal of virus control weapons against endemic and epizootic viral diseases.

Contact Information

Website
www.virovet.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Animal Husbandry
Biotechnology
Primary Office
  • Ambachtenlaan 1
  • 3001 Leuven
  • Belgium
+32 016 00 00 00

ViroVet Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

ViroVet Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Early Stage VC (Series B) 04-Jun-2020 $6.67M 000.00 000.00 Completed Generating Revenue
3. Grant 19-Sep-2018 00000 000.00 Completed Generating Revenue
2. Early Stage VC 28-Aug-2018 $3.46M $11.2M 00.00 Completed Generating Revenue
1. Early Stage VC (Series A) 09-Oct-2017 $7.7M $7.7M Completed Generating Revenue
To view ViroVet’s complete valuation and funding history, request access »

ViroVet Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Preferred B 00,000 000.00 000.00 00 000.00 00.000
Preferred B 00,000 000.00 000.00 00 000.00 00.00
Preferred A 105,458 $65.65 $65.65 1x $65.65 50.43%
Ordinary A 16,666 $65.65 $65.65 1x $65.65 7.97%
To view ViroVet’s complete cap table history, request access »

ViroVet Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of antiviral drugs designed to control the spread of viral diseases in livestock. The company's drugs are mean
Drug Discovery
Leuven, Belgium
18 As of 2020
000.00
00.00 0000-00-00
00000000000 000.00

0000000

eprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat
0000000000000
Morrisville, NC
00 As of 0000
0000
0000000000 0000

000000 0

onsequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nul
0000 000000000
Durham, NC
00 As of 0000
000.00
0000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ViroVet Competitors (2)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Applied LifeSciences & Systems Venture Capital-Backed Morrisville, NC 00 0000 0000000000 0000
000000 00000000 Venture Capital-Backed Durham, NC 00 000.00 0000000000 000.00
You’re viewing 2 of 2 competitors. Get the full list »

ViroVet Executive Team (4)

Name Title Board Seat Contact Info
Erwin Blomsma Ph.D Co-Founder, Chief Executive Officer & Board Member
Stefaan Wera Co-Founder & Chief Operating Officer
Nesya Goris Ph.D Co-Founder & Chief Development Officer
Johan Neyts Ph.D Chief Scientific Officer
To view ViroVet’s complete executive team members history, request access »

ViroVet Board Members (11)

Name Representing Role Since
Erwin Blomsma Ph.D ViroVet Co-Founder, Chief Executive Officer & Board Member 000 0000
George Gunn Ph.D Self Chairman 000 0000
Ilse Sienaert Ph.D Self Board Member 000 0000
Kenneth Wils ViroVet Board Member 000 0000
Laetitia Gerbe Self Board Member 000 0000
You’re viewing 5 of 11 board members. Get the full list »

ViroVet Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ViroVet Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Seventure Partners Venture Capital Minority 000 0000 000000 0
Horizon 2020 Government 000 0000 000000 0
Vlaams Agentschap Innoveren en Ondernemen Endowment Limited Partner 000 0000 000000 0
Agri Investment Fund PE/Buyout Minority 000 0000 000000 0
Aratana Therapeutics Corporation Minority 000 0000 000000 0
You’re viewing 5 of 10 investors. Get the full list »